Follow us on Bluesky
Bluesky · Hashtag

#dialysis

17
posts · 30d
14
users
1
posts / day
1.2
posts / user
+ 50% vs last week

#dialysis is an active hashtag on Bluesky. In the last 30 days, 14 people shared 17 posts with it — around 1 a day. Activity is up 50% versus the previous week, peaking on Nov 3 with 4 posts.

#dialysis posts per day (last 30 days)

Related tags

Tags most often used together with #dialysis.

#Nephrology 6

Posts with #dialysis

Midgard Finance 🇪🇺
@midgardfinance.eu
6 days ago
🩺 #dialysis 🇩🇪 $FME Fresenius Medical Care Q3 revenue EUR 4,937m, operating income EUR 545m excl. EUR 161m special items: -1% and -6% at constant currency. 2026 operating income guide narrowed: flat to down mid-single digit, was up or down mid-single digit midgardfinance.com/compan…
Two bar charts titled "FME: US treatments and price, % change". Left: US same market treatment growth, which leaves out closed and sold clinics, by quarter from Q1 23 to Q3 26, from −0.3%, a high of +0.4% in Q4 24, then +0.1% in Q3 25, −0.2%, −0.4%, −0.9% and −1.1% in Q3 26. Right: price effects from Q2 25, organic growth less treatment growth, our subtraction, 3.4, 5.7, 8.2, 7.1, 7.6 and 2.3. They start in Q2 25, when Value-Based Care left the US clinic line. Price holds Medicare's temporary add-on payment for new dialysis drugs, which helped in the first half of 2026 and turned to a headwind in the third quarter, and also payor mix and billing effects. The company says favourable rate effects were offset by that payment, and in October called the first half's fall in treatments a volume capture issue. Treatments were 0.0% in Q3 24, Q1 25 and Q2 25.
Grouped bar chart titled "FME: adjusted operating income, EUR m". 2025 against 2026 at constant currency, EUR m: Q1 457 and 501, Q2 476 and 588, Q3 574 and 541, which is 545 at actual rates. Q4 2025 was 705, which the company called exceptional. Our arithmetic for Q4 2026, the full-year range less nine months: the earlier outlook implied 470 to 692, the new one 470 to 581, taking mid-single digit as 5%. The new outlook's top, 581, is its flat end and needs no such reading. The company expects its largest headwinds from the Medicare payment in Q4. Shervin Korangy, CEO since 12 October: "We are muted in our assessment of performance".
Grouped bar chart titled "FME: special items, EUR m", by quarter from Q1 25 to Q3 26, EUR m. FME25+ restructuring: 28, 53, 41, 73, 166, 42, 54, in every quarter; 166 in Q1 26 mainly US clinic closures. Leaving businesses and markets: 24, 6, 50, 18, 12, −3, 98; Q3 26 holds the release's EUR 108m for ending local production and sale of the 4008A machine and leaving peritoneal dialysis in China, and other items of −10, our subtraction. Humacyte remeasurements, the Tavneos impairment at a joint venture and other: 74, −8, 6, 20, 3, 64, 9. The sum in Q3 26 was 161 against 97 a year earlier.
Bridge chart titled "FME: EPS excl. special items, Q3 to Q3, EUR", from EUR 1.10 in Q3 2025 to EUR 1.11 in Q3 2026, at actual exchange rates, in rounded steps that add up, our breakdown: operating income −0.10, interest cost −0.02, tax +0.06, minority holders −0.04, and 10% fewer shares +0.11. Net income excl. special items fell 9.6%, so the buyback holds EPS level. Reported EPS, with special items, was EUR 0.61 against EUR 0.94; Q3 2025 reported net income also held a EUR 35m Interwell Health tax gain.
1 0 3
@pin5y.bsky.social
1 day ago
This tech … she poke me 2x already and I’m the problem … laughable! And they say they’re professionals #dialysis
0 0 0
Midgard Finance
@midgardfinance.com
6 days ago
🩺 #dialysis 🇩🇪 $FME Fresenius Medical Care Q3 revenue EUR 4,937m, operating income EUR 545m excl. EUR 161m special items: -1% and -6% at constant currency. 2026 operating income guide narrowed: flat to down mid-single digit, was up or down mid-single digit midgardfinance.com/compan…
Two bar charts titled "FME: US treatments and price, % change". Left: US same market treatment growth, which leaves out closed and sold clinics, by quarter from Q1 23 to Q3 26, from −0.3%, a high of +0.4% in Q4 24, then +0.1% in Q3 25, −0.2%, −0.4%, −0.9% and −1.1% in Q3 26. Right: price effects from Q2 25, organic growth less treatment growth, our subtraction, 3.4, 5.7, 8.2, 7.1, 7.6 and 2.3. They start in Q2 25, when Value-Based Care left the US clinic line. Price holds Medicare's temporary add-on payment for new dialysis drugs, which helped in the first half of 2026 and turned to a headwind in the third quarter, and also payor mix and billing effects. The company says favourable rate effects were offset by that payment, and in October called the first half's fall in treatments a volume capture issue. Treatments were 0.0% in Q3 24, Q1 25 and Q2 25.
Grouped bar chart titled "FME: adjusted operating income, EUR m". 2025 against 2026 at constant currency, EUR m: Q1 457 and 501, Q2 476 and 588, Q3 574 and 541, which is 545 at actual rates. Q4 2025 was 705, which the company called exceptional. Our arithmetic for Q4 2026, the full-year range less nine months: the earlier outlook implied 470 to 692, the new one 470 to 581, taking mid-single digit as 5%. The new outlook's top, 581, is its flat end and needs no such reading. The company expects its largest headwinds from the Medicare payment in Q4. Shervin Korangy, CEO since 12 October: "We are muted in our assessment of performance".
Grouped bar chart titled "FME: special items, EUR m", by quarter from Q1 25 to Q3 26, EUR m. FME25+ restructuring: 28, 53, 41, 73, 166, 42, 54, in every quarter; 166 in Q1 26 mainly US clinic closures. Leaving businesses and markets: 24, 6, 50, 18, 12, −3, 98; Q3 26 holds the release's EUR 108m for ending local production and sale of the 4008A machine and leaving peritoneal dialysis in China, and other items of −10, our subtraction. Humacyte remeasurements, the Tavneos impairment at a joint venture and other: 74, −8, 6, 20, 3, 64, 9. The sum in Q3 26 was 161 against 97 a year earlier.
Bridge chart titled "FME: EPS excl. special items, Q3 to Q3, EUR", from EUR 1.10 in Q3 2025 to EUR 1.11 in Q3 2026, at actual exchange rates, in rounded steps that add up, our breakdown: operating income −0.10, interest cost −0.02, tax +0.06, minority holders −0.04, and 10% fewer shares +0.11. Net income excl. special items fell 9.6%, so the buyback holds EPS level. Reported EPS, with special items, was EUR 0.61 against EUR 0.94; Q3 2025 reported net income also held a EUR 35m Interwell Health tax gain.
1 0 2
ISNkidneycare
@theisn.org
4 days ago
The trial compared preparation for dialysis with conservative kidney management in older people approaching kidney failure. 🎥 Missed the webinar? Stay tuned for the recording on ISN Academy. #Nephrology #KidneyCare #Dialysis #ISNWebinars
0 0 0
Rolando Claure
@runningkidneys.bsky.social
17 days ago
🩸 Hemoadsorption in maintenance HD: promising results! Shanghai multicenter RCT (n=1,407): ⬇️ All-cause mortality: 22% (HR 0.78) ⬇️ CV mortality: 34% (HR 0.66) ⬇️ Major CV events: 23% (HR 0.77) Benefits vs mostly low-flux HD. Important context! #KidneyWk #Dialysis
0 1 0
The Pharmaceutical Journal
@pharmaj.bsky.social
19 days ago
In our latest learning article, #MaryamKhorsandi provides an overview of the progression of diabetic kidney disease, the challenges of managing #diabetes on #dialysis and considerations for monitoring patients #ukpharmacy #kidneydisease buff.ly/FgNLiyE
Adults with diabetes on dialysis

buff.ly

Adults with diabetes on dialysis

Introduction Kidney failure is among the most serious outcomes of diabetes mellitus. Diabetes is the leading cause of kidney failure, both worldwide and in the UK​1,2​. In 2022, nearly 520,000 people…
0 0 0
Dialysis Log
@dialysislogapp.bsky.social
20 days ago
We built Dialysis Log, a free dialysis & fluid tracker. Log sessions and drinks against the limit you enter. No account, works offline, data stays on your phone. We're not patients, so tell us what's missing. Not medical advice. #dialysis pocketappstudio.github.io….
Video thumbnail
Play button
0 0 1
Nature Medicine
@natmed.nature.com
25 days ago
📢Webinar: Join Nature Medicine & Nature Reviews Nephrology for a discussion on approaches to financing #dialysis, a leading cause of catastrophic health expenditure Wednesday, Oct 21 With Valerie Luyckx, Ole Norheim, Laura Sola, Yot Teerawattananon @natrevneph.nature.com cassyni.com/events/5PxZX...

cassyni.com

Financing kidney replacement therapy

In 2025, The World Health Organization adopted a historic resolution that recognises kidney disease as a global health priority and calls on Member States to include kidney care services in universal ...
0 3 1

Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.

View all posts on Bluesky

Explore trending tags

#art #Halloween #oc #nsfw #furry #digitalart #fanart #furryart #AI #Vote #photography #gamedev
Back to all tags